On September 14, 2022, Prometheus Laboratories Inc. (‘Prometheus') announced its partnership with Takeda Pharmaceutical Company Limited (‘Takeda') to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients. CDPATH is a personalized risk assessment tool that can be used in combination with a physician's clinical assessment to evaluate an adult patient's risk for developing serious complications of CD such as bowel strictures, internal penetrating disease, or non-perianal surgery within three years. The CDPATH test is a result of a collaboration among Prometheus, MiTest Health LLC (‘MiTest') and Takeda Pharmaceutical Company Limited (‘Takeda').

MiTest defined and established the clinical relevance of the CDPATH model through an independent clinical study. Prometheus, a CLIA certified and CAP accredited laboratory, validated CDPATH and is the processing laboratory for the CDPATH program. Takeda will make CDPATH available for use by US-based physicians and offer the test free of charge to eligible patients, with the goal of supporting shared decision-making between patients and healthcare providers.

This partnership with Takeda contributes to the Prometheus mission of enabling precision-guided patient care and improving disease outcomes.